UCB is a leading global biopharmaceutical company dedicated to the research, development and commercialisation of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy and respiratory diseases, immune and inflammatory disorders and oncology. Headquartered in Brussels, UCB employs over 8,500 people operating in more than 40 countries.

UCB uses innovative approaches to drug discovery and has an unmatched combination of expertise in both chemically-derived medicines (small molecules) and biologics. We have restructured our small-molecule research capability into three Centres of Excellence, each focusing on a different therapeutic area. Our Cambridge site focuses on inflammation research, including multiple sclerosis.